XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Cash flows from operating activities:    
Net income (loss) $ (4,542,078) $ (28,779)
Adjustments to reconcile net loss to net cash provided by operating activities:    
Depreciation and amortization expense 3,406,166 3,702,687
Amortization of operating lease right-of-use assets 855,553 709,021
Share-based compensation 227,083 271,146
Decrease in non-cash contingent consideration (936,072) (1,017,712)
Decrease (Increase) of life insurance policies over premiums paid (180,081) 16,357
Noncash interest expense 19,377 11,713
Loss on disposal of assets 2,691 0
Life insurance proceeds (237,089) (346,800)
Net changes in assets and liabilities affecting operating activities:    
Accounts receivable (1,552,449) 890,361
Inventories 1,072,295 418,355
Other current assets and other assets 1,022,718 1,053,432
Operating lease liabilities (645,009) (2,201,773)
Accounts payable and other current liabilities (667,065) 1,903,021
Other long-term liabilities (362,844) (327,329)
Net cash provided by (used in) operating activities (2,516,804) 5,053,700
Cash flows from investing activities:    
Additions to property and equipment (64,178) (232,595)
Life insurance policy proceeds received 237,556 0
Additions to intangible assets (88,727) (133,739)
Net cash provided by (used in) investing activities 84,651 (366,334)
Cash flows from financing activities:    
Borrowings on line of credit 32,988,920 23,775,000
Payments on line of credit (29,681,472) (27,051,875)
Cash settlement of contingent consideration (1,251,499) (2,108,933)
Payments made in connection with repurchase of common shares (480,666) (551,563)
Net cash provided by (used in) financing activities 1,575,283 (5,937,371)
Net decrease in cash and cash equivalents (856,870) (1,250,005)
Cash and cash equivalents at beginning of period 18,321,624 19,757,970
Cash and cash equivalents at end of period $ 17,464,754 $ 18,507,965